Botulinum toxin type a reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain

Pain Medicine (United States)

Volumn 14, Issue 2, 2013, Pages 276-286

  Xiao, Lizu ^a   Cheng, Jianguo ^d   Zhuang, Yu ^b   Qu, Wenchun ^e   Muir, Jeffery ^e   Liang, Haowen ^c   Zhang, Deren ^c  

^a Shenzhen No 2 People s Hospital   (China)

^b HUIZHOU MUNICIPAL CENTRAL HOSPITAL   (China)

^c Shenzhen Nanshan People s Hospital and the 6th Affiliated Hospital of Shenzhen University Medical School   (China)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

Botulinum Toxin Type A (BTX A); Hyperalgesia; Lumbar 5 Ventral Root Transection; Neuropathic Pain; Transient Receptor Potential Vanilloid Type 1 (TRPV1)

Indexed keywords

4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; BOTULINUM TOXIN A; SODIUM CHLORIDE;

ANALGESIC ACTIVITY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DORSAL ROOT; DOSE RESPONSE; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; LUMBAR SPINE; MALE; NERVE TRANSECTION; NEUROPATHIC PAIN; NONHUMAN; PAIN RECEPTOR; PAIN THRESHOLD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN EXPRESSION; RAT; SPINAL GANGLION; UPREGULATION; VENTRAL ROOT; WESTERN BLOTTING;

EID: 84874518368     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12017     Document Type: Article

References (48)

1. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008;64:274-283.
2. Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 2002;18:S177-181.
3. Carroll I, Clark JD, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol 2009;65:348-351.
4. Turk U, Ilhan S, Alp R, Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005;28:161-162.
5. Xiao L, Mackey S, Hui H, etal. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med 2010;11:1827-1833.
6. Yuan RY, Sheu JJ, Yu JM, etal. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology 2009;72:1473-1478.
7. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(suppl 1):S16-24.
8. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004;279:25665-25672.
9. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009;141:60-69.
10. Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 2006;122:315-325.
11. Apostolidis A, Popat R, Yiangou Y, etal. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977-982; discussion 82-3.
12. Brady CM, Apostolidis A, Yiangou Y, etal. P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. Eur Urol 2004;46:247-253.
13. Brady CM, Apostolidis AN, Harper M, etal. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 2004;93:770-776.
14. Smet PJ, Moore KH, Jonavicius J. Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 1997;77:37-49.
15. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-793.
16. Ha US, Park EY, Kim JC. Effect of botulinum toxin on expression of nerve growth factor and transient receptor potential vanilloid 1 in urothelium and detrusor muscle of rats with bladder outlet obstruction-induced detrusor overactivity. Urology 2011;78:721 e1-7216.
17. Li L, Xian CJ, Zhong JH, Zhou XF. Effect of lumbar 5 ventral root transection on pain behaviors: A novel rat model for neuropathic pain without axotomy of primary sensory neurons. Exp Neurol 2002;175:23-34.
18. Sheth RN, Dorsi MJ, Li Y, etal. Mechanical hyperalgesia after an L5 ventral rhizotomy or an L5 ganglionectomy in the rat. Pain 2002;96:63-72.
19. Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain 2006;123:306-321.
20. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-110.
21. Xiao L, Cheng J, Dai J, Zhang D. Botulinum toxin decreases hyperalgesia and inhibits P2X(3) receptor over-expression in sensory neurons induced by ventral root transection in rats. Pain Med 2011;12:1385-1394.
22. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55-63.
23. Decosterd I, Woolf CJ. Spared nerve injury: An animal model of persistent peripheral neuropathic pain. Pain 2000;87:149-158.
24. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88.
25. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002;36:57-68.
26. Schafers M, Svensson CI, Sommer C, Sorkin LS. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 2003;23:2517-2521.
27. Xin WJ, Gong QJ, Xu JT, etal. Role of phosphorylation of ERK in induction and maintenance of LTP of the C-fiber evoked field potentials in spinal dorsal horn. J Neurosci Res 2006;84:934-943.
28. Bernardini N, Neuhuber W, Reeh PW, Sauer SK. Morphological evidence for functional capsaicin receptor expression and calcitonin gene-related peptide exocytosis in isolated peripheral nerve axons of the mouse. Neuroscience 2004;126:585-590.
29. Caterina MJ, Schumacher MA, Tominaga M, etal. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 1997;389:816-824.
30. Fischer MJ, Reeh PW, Sauer SK. Proton-induced calcitonin gene-related peptide release from rat sciatic nerve axons, in vitro, involving TRPV1. Eur J Neurosci 2003;18:803-810.
31. Holzer P. Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 1991;43:143-201.
32. Price TJ, Flores CM. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential vanilloid subfamily type 1 immunoreactivities, and isolectin B4 binding in primary afferent neurons of the rat and mouse. J Pain 2007;8:263-272.
33. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol 2006;68:619-647.
34. Szallasi A, Blumberg PM. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-212.
35. Biro T, Bodo E, Telek A, etal. Hair cycle control by vanilloid receptor-1 (TRPV1): Evidence from TRPV1 knockout mice. J Invest Dermatol 2006;126:1909-1912.
36. Bodo E, Biro T, Telek A, etal. A hot new twist to hair biology: Involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol 2005;166:985-998.
37. Inoue K, Koizumi S, Fuziwara S, Denda S, Denda M. Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun 2002;291:124-129.
38. Mezey E, Toth ZE, Cortright DN, etal. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 2000;97:3655-3660.
39. Siegmund SV, Uchinami H, Osawa Y, Brenner DA, Schwabe RF. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005;41:1085-1095.
40. Stander S, Moormann C, Schumacher M, etal. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol 2004;13:129-139.
41. Nilius B, Voets T. TRP channels: A TR(I)P through a world of multifunctional cation channels. Pflugers Arch 2005;451:1-10.
42. Bach-Rojecky L, Salkovic-Petrisic M, Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. Eur J Pharmacol 2010;633:10-14.
43. Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133.
44. Favre-Guilmard C, Auguet M, Chabrier PE. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol 2009;617:48-53.
45. Burnstock G. Purine-mediated signalling in pain and visceral perception. Trends Pharmacol Sci 2001;22:182-188.
46. Guo A, Vulchanova L, Wang J, Li X, Elde R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): Relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 1999;11:946-958.
47. Apostolidis A, Popat R, Yiangou Y, etal. Successful clinical outcome of intra-detrusor Botulinum toxin for human detrusor overactivity is not associated with suburothelial neuronal or cholinergic fibre degeneration or sprouting. J Endourol 2004;18:A23-170.
48. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011;17(suppl 1):S28-33.